Immatics is the global leader in precision targeting of PRAME
About us
Immatics has the broadest PRAME franchise with the most indications and therapeutic modalities.
Explore the pipeline
PRAME is expressed
in >50 cancers
PRAME is a target expressed in more than 50 cancers, including melanoma, lung, ovarian, breast, and endometrial cancer, among many others. Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. To do so safely and effectively requires deep expertise in immunology, drug development and beyond.
Science explained
Clinical trials
Immatics is evaluating its targeted PRAME cell therapies and bispecific product candidates and actively enrolling patients in ongoing clinical trials.
Clinical trials
